Crosslay Remedies Limited, a active public limited company, was established on 08 January 2002 in Delhi, India. Engaging in hospitals within the hospital and medical care sector, it holds CIN: U24239DL2002PLC113719. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹157.00 Cr and a paid-up capital of ₹143.19 Cr.
Formerly known as Crosslay Remedies Private Limited. It upholds a compliant status. Employing 1,434 professional, Its leadership includes Yogesh Kumar Sareen (Director), Vandana Ramesh Pakle (Director), Mradul Kaushik (Director). Past directors included Girish Narang, Navneet Maini, Mahendra Gumanmalji Lodha. It holds ₹250.00 Cr open charges and ₹983.96 Cr settled loans. Its latest AGM occurred on 29 August 2024, with the balance sheet filed on 31 March 2024. It is based at N-110, Panchsheel Park India, New Delhi, Delhi, 110017.
U24239DL2002PLC113719
113719
08 January 2002
₹157.00 Cr
₹143.19 Cr
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Crosslay Remedies Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Yogesh Kumar Sareen | Director | 10 Jul 2015 | Current |
| Vandana Ramesh Pakle | Director | 04 Feb 2020 | Current |
| Mradul Kaushik | Director | 18 Oct 2019 | Current |
| Anas Abdul Wajid | Director | 01 Jan 2019 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 22 Jun 2022 | Past |
| Pramod Abcsdd | Director | - | Past |
| Pramod Abcsdd | Additional Director | 01 Jul 2022 | Past |
| Pramod Abcsdd | Wholetime Director | 10 Jul 2015 | Past |
| Pramod Abcsdd | Director | - | Past |
| Pramod Abcsdd | Wholetime Director | 10 Jul 2015 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Crosslay Remedies Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.13% increase. The company also saw a substantial improvement in profitability, with a 40.61% increase in profit. The company's net worth Soared by an impressive increase of 58.71%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Crosslay Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,500,000,000.00
₹9,839,603,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Dec 2020 | Others | ₹200.00 Cr | Open |
| 23 Dec 2020 | Others | ₹50.00 Cr | Open |
| 20 Nov 2018 | Axis Bank Limited | ₹75.00 Cr | Satisfied |
| 24 Feb 2016 | Others | ₹180.00 Cr | Satisfied |
| 31 Mar 2015 | Punjab National Bank | ₹2.50 Cr | Satisfied |
Explore comprehensive loan charge details -
Crosslay Remedies has a workforce of 1434 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Crosslay Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crosslay Remedies's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Crosslay Remedies Limited last Annual general meeting of members was held on 29 Aug 2024 as per latest MCA records. was documented.
Crosslay Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
A charge with Others of Rs. 50.00 Cr registered on 23 Dec 2020 with Charge ID 100405347 was modified on 05 Feb 2024. was recorded as a recent event.
Umang Jaiswal was appointed as a Cfo was appointed as a Cfo on 02 Feb 2023 & has been associated with this company since 2 years 4 months . was recorded as a recent event.
A charge with Others of Rs. 200.00 Cr registered on 25 Dec 2020 with Charge ID 100405633 was modified on 14 Feb 2022. was recorded as a recent event.
Progress on A charge registered on 20 Nov 2018 via Charge ID 100221293 with Axis Bank Limited was fully satisfied on 09 Apr 2021. was documented.
Max Healthcare Institute Ltd on Wednesday reported a 26% growth in its profit after tax at ₹338 crore in the December quarter. The company posted a Profit After Tax (PAT) of ₹269 crore in the third quarter of FY23.
The company completed the acquisition of additional 34,000 equity shares having a face value of Rs 10 each fully paid up of Eqova Max Healthcare Institute had earlier entered into a share purchase ag.
The CIN of Crosslay Remedies Limited is U24239DL2002PLC113719.
Crosslay Remedies Limited is headquartered at N-110, Panchsheel Park India, New Delhi, Delhi, 110017.
Crosslay Remedies Limited was incorporated on 08 January 2002.
The current directors of Crosslay Remedies Limited are
The primary industry of Crosslay Remedies Limited is Hospital And Medical Care.
Crosslay Remedies Limited is unlisted.
The authorized capital of Crosslay Remedies Limited is ₹157.00 Cr, and the paid-up capital is ₹143.19 Cr.
The compliance status of Crosslay Remedies Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX